Different Nanotechnology Approaches for Ciprofloxacin Delivery Against Multidrug-Resistant Microbes

References

• World Heath Organization. Bibliography of scientific publications on antimicrobial resistance from South-East Asia Region, Printed in India. © World Health Organization; 2011.
   Google Scholar
• Gashe F, Mulisa E, Mekonnen M, Zeleke G. Antimicrobial resistance profile of different clinical isolates against third-generation cephalosporins. J Pharmaceut. 2018;2018:1–7. doi:10.1155/2018/5070742
   Web of Science ®Google Scholar
• Pham TDM, Ziora ZM, Blaskovich MAT. Quinolone Antibiotics. Med Chem Commun. 2019;10(10):1719–1739. doi:10.1039/C9MD00120D
   Web of Science ®Google Scholar
• Sharma D, Patel RP, Zaidi STR, Sarker MMR, Lean QY, Ming LC. Interplay of the quality of ciprofloxacin and antibiotic resistance in developing countries. Front Pharmacol. 2017;8:546. doi:10.3389/fphar.2017.00546
   PubMed Web of Science ®Google Scholar
• Vidyavathi M, Srividya G. A review on ciprofloxacin: dosage form perspective. Int J Appl Pharmaceut. 2018;10(4):6. doi:10.22159/ijap.2018v10i4.25315
   Google Scholar
• Reis ACC, Santos SRS, Souza SC, Saldanha MG, Pitanga TN, Oliveira RR. Ciprofloxacin resistance pattern among bacteria isolated from patients with community-acquired urinary tract infection. Rev Inst Med Trop Sao Paulo. 2016;58:53. doi:10.1590/S1678-9946201658053
   Web of Science ®Google Scholar
• Mulder M, de Jong JCK, Goessens WHF, et al. Risk factors for resistance to ciprofloxacin in community-acquired urinary tract infections due to Escherichia coli in an elderly population. J Antimicrob Chemother. 2017;72:281–289. doi:10.1093/jac/dkw399
   Web of Science ®Google Scholar
• Lee C-R, Cho I, Jeong B, Lee S. Strategies to minimize antibiotic resistance. Int J Environ Res Public Health. 2013;10(9):4274–4305.
   PubMed Web of Science ®Google Scholar
• Aruguete DM, Kim B, Hochella MF, et al. Antimicrobial nanotechnology: its potential for the effective management of microbial drug resistance and implications for research needs in microbial nanotoxicology. Environ Sci Processes Impacts. 2013;15(1):93–102.
   PubMed Web of Science ®Google Scholar
• Baptista PV, McCusker MP, Carvalho A, et al. Nano-strategies to fight multidrug resistant bacteria — “A Battle of the Titans”. Front Microbiol. 2018;9:1441.
   PubMed Web of Science ®Google Scholar
• Rehman A, Patrick WM, Lamont IL. Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: new approaches to an old problem. J Med Microbiol. 2019;68(1):1–10. doi:10.1099/jmm.0.000873
   PubMed Web of Science ®Google Scholar
• Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis. 2003;9(1). doi:10.3201/eid0901.020277
   Web of Science ®Google Scholar
• Ahmad I, Ahmad S, Rumbaugh KP, Editors. Antibacterial Drug Discovery to Combat MDR. Singapore: © Springer Nature Singapore Pte Ltd; 2019.
   Google Scholar
• Hamed SM, Elkhatib WF, El-Mahallawy HA, Helmy MM, Ashour MS, Aboshanab KMA. Multiple mechanisms contributing to ciprofloxacin resistance among gram negative bacteria causing infections to cancer patients. Sci Rep. 2018;8(1):12268. doi:10.1038/s41598-018-30756-4
   PubMed Web of Science ®Google Scholar
• Campion JJ, McNamara JJ, Evans ME. Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments. Antimicrob Agents Chemother. 2004;48(12):4733–4744. doi:10.1128/AAC.48.12.4733-4744.2004
   Web of Science ®Google Scholar
• Cirz RT, Romesberg FE. Induction and inhibition of ciprofloxacin resistance-conferring mutations in hypermutator bacteria. Antimicrob Agents Chemother. 2006;50(1):220–225. doi:10.1128/AAC.50.1.220-225.2006
   PubMed Web of Science ®Google Scholar
• Zhao F, Yang H, Bi D, Khaledi A, Qiao M. A systematic review and meta-analysis of antibiotic resistance patterns, and the correlation between biofilm formation with virulence factors in uropathogenic E. coli isolated from urinary tract infections. Microb Pathog. 2020;144:104196. doi:10.1016/j.micpath.2020.104196
   Web of Science ®Google Scholar
• O’Regan E, Quinn T, Frye JG, et al. Fitness costs and stability of a high-level ciprofloxacin resistance phenotype in Salmonella enterica serotype Enteritidis: reduced infectivity associated with decreased expression of Salmonella pathogenicity Island 1 genes. Antimicrob Agents Chemother. 2010;54(1):367–374. doi:10.1128/AAC.00801-09
   Web of Science ®Google Scholar
• Ghaffari S, Varshosaz J, Haririan I, Khoshayand MR, Azarmi S, Gazori T. Ciprofloxacin loaded Alginate/Chitosan and solid lipid nanoparticles, preparation, and characterization. J Dispers Sci Technol. 2012;33(5):685–689. doi:10.1080/01932691.2011.579831
   Web of Science ®Google Scholar
• Kumar S, Bhanjana G, Kumar A, Taneja K, Dilbaghi N, Kim K-H. Synthesis and optimization of ceftriaxone-loaded solid lipid nanocarriers. Chem Phys Lipids. 2016;200:126–132. doi:10.1016/j.chemphyslip.2016.09.002
   PubMed Web of Science ®Google Scholar
• Bali GK, Singla S, Kashyap Y, et al. Preparation, physico-chemical characterization and pharmacodynamics of ceftriaxone loaded BSA nanoparticles. J Nanomed Nanotechnol. 2018;9:509. doi:10.4172/2157-7439.1000509
   Google Scholar
• Jaison J, Barhoum A, Chan YS, Dufresne A, Danquah MK. Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. Beilstein J Nanotechnol. 2018;9:1050–1074. doi:10.3762/bjnano.9.98
   Web of Science ®Google Scholar
• Patel S, Singh D, Srivastava S, et al. Nanoparticles as a platform for antimicrobial drug delivery. Adv Pharmacol Pharm. 2017;5(3):31–43. doi:10.13189/app.2017.050301
   Web of Science ®Google Scholar
• Sobhani Z, Samani SM, Montaseri H, Khezri E. Nanoparticles of chitosan loaded ciprofloxacin: fabrication and antimicrobial activity. Adv Pharm Bull. 2017;7(3):427–432. doi:10.15171/apb.2017.051
   PubMed Web of Science ®Google Scholar
• Marei N, Elwahy AHM, Salah TA, El Sherif Y, El-Samie EA. Enhanced antibacterial activity of Egyptian local insects’ chitosan-based nanoparticles loaded with ciprofloxacin-HCl. Biomac. 2019;126:262–272.
   Google Scholar
• Shafiei S, Hassanshahian M, Shakeri S, Hamayeli H. Evaluation the antibacterial activity of nanoantibiotics imipenem and ciprofloxacin loaded in human serum albumin against some antibiotic-resistant pathogenic bacteria. J Exper Nanosci. 2020;15(1):350–362. doi:10.1080/17458080.2020.1796978
   Web of Science ®Google Scholar
• Mudakavi RJ, Vanamali S, Chakravortty D, Raichur AM. Development of arginine based nanocarriers for targeting and treatment of intracellular Salmonella. RSC Adv. 2017;7(12):7022. doi:10.1039/C6RA27868J
   Web of Science ®Google Scholar
• Dizaj SM, Lotfipour F, Barzegar-Jalali M, Zarrintan M, Adibkia K. Ciprofloxacin HCl-loaded calcium carbonate nanoparticles: preparation, solid state characterization, and evaluation of antimicrobial effect against. Artif Cells Nanomed Biotechnol. 2017;45(3):535–543. doi:10.3109/21691401.2016.1161637
   Web of Science ®Google Scholar
• Günday C, Anand S, Gencer HB, et al. Ciprofloxacin-loaded polymeric nanoparticles incorporated electrospun fibers for drug delivery in tissue engineering applications. Drug Deliv Transl Res. 2020;10(3):706–720. doi:10.1007/s13346-020-00736-1
   PubMed Web of Science ®Google Scholar
• Dilbaghi N, Kaur H, Ahuja M, Arora P, Kumar S. Synthesis and evaluation of ciprofloxacin-loaded carboxymethyl tamarind kernel polysaccharide nanoparticles. J Exper Nanosci. 2014;9(10):1015–1025. doi:10.1080/17458080.2013.771244
   Web of Science ®Google Scholar
• Torge A, Wagner S, Chaves PS, et al. Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis. Int J Pharm. 2017;527(1–2):92–102. doi:10.1016/j.ijpharm.2017.05.013
   PubMed Web of Science ®Google Scholar
• Ghosh S, Qi R, Carter KA, Zhang G, Pfeifer BA, Lovell JF. Loading and releasing ciprofloxacin in photoactivatable liposomes. Biochem Eng J. 2019;141:43–48. doi:10.1016/j.bej.2018.10.008
   Web of Science ®Google Scholar
• Westmeier D, Siemer S, Vallet C, et al. Boosting nanotoxicity to combat multidrug-resistant bacteria in pathophysiological environments. Nanoscale Adv. 2020;2(11):5428–5440. doi:10.1039/D0NA00644K
   Web of Science ®Google Scholar
• Siemer S, Westmeier D, Vallet C, et al. Resistance to nano-based antifungals is mediated by biomolecule coronas. ACS Appl Mater Interfaces. 2019;11(1):104–114. doi:10.1021/acsami.8b12175
   PubMed Web of Science ®Google Scholar
• Niño-Martínez N, Orozco NFS, Martínez-Castañón G-A, Méndez FT, Ruiz F. Molecular mechanisms of bacterial resistance to metal and metal oxide nanoparticles. Int J Mol Sci. 2019;20(11):2808. doi:10.3390/ijms20112808
   Web of Science ®Google Scholar
• Salas-Orozco M, Niño-Martínez N, Martínez-Castañón G-A, et al. Mechanisms of resistance to silver nanoparticles in endodontic bacteria: a literature review. J Nanomater. 2019;2019. doi:10.1155/2019/7630316
   Web of Science ®Google Scholar
• Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives. Biomater Sci. 2020;8(17):4653–4664. doi:10.1039/D0BM00558D
   PubMed Web of Science ®Google Scholar
• Manimekalai P, Manavalan R. Selection of excipients for the formulation of Ceftriaxone sodium loaded chitosan nanoparticle through drug-excipient compatibility testing. Int J PharmTech Res. 2015;8(1):5–10.
   Google Scholar
• Kucukoglu V, Uzuner H, Kenar H, Karadenizli A. In vitro antibacterial activity of ciprofloxacin loaded chitosan microparticles and their effects on human lung epithelial cells. Int J Pharm. 2019;569:118578. doi:10.1016/j.ijpharm.2019.118578
   PubMed Web of Science ®Google Scholar
• Mahdavinia GR, Karimi MH, Soltaniniya M, Massoumi B. In vitro evaluation of sustained ciprofloxacin release from κ-carrageenan-crosslinked chitosan/hydroxyapatite hydrogel nanocomposites. Int J Biol Macromol. 2019;126:443–453. doi:10.1016/j.ijbiomac.2018.12.240
   Web of Science ®Google Scholar
• Raveendran NT, Mohandas A, Menon RR, Menon AS, Biswas R, Jayakumar R. Ciprofloxacin and fluconazole containing fibrin nanoparticles incorporated chitosan bandages for the treatment of polymicrobial wound infections. ACS Appl Bio Mater. 2018;2(1):243–254.
   Google Scholar
• Gnanadhas DP, Thomas MB, Elango M, Raichur AM, Chakravortty D. Chitosan-dextran sulphate nanocapsule drug delivery system as an effective therapeutic against intraphagosomal pathogen Salmonella. J Antimicrob Chemother. 2013;68(11):2576–2586. doi:10.1093/jac/dkt252
   PubMed Web of Science ®Google Scholar
• Kumar GV, Su CH, Velusamy P. Ciprofloxacin loaded genipin cross-linked chitosan/heparin nanoparticles for drug delivery application. Mater Lett. 2016;180:119–122. doi:10.1016/j.matlet.2016.05.108
   Web of Science ®Google Scholar
• Buck E, Maisuria V, Tufenkji N, Cerruti M. Antibacterial properties of PLGA electrospun scaffolds containing ciprofloxacin incorporated by blending or physisorption. ACS Appl Bio Mater. 2018;1(3):627–635. doi:10.1021/acsabm.8b00112
   PubMedGoogle Scholar
• Türeli NG, Torge A, Juntke J, et al. Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections. Eur J Pharmaceut Biopharmaceut. 2017;17:363–371.
   Web of Science ®Google Scholar
• Türeli NG, Türeli AE, Schneider M. Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: design of experiments approach. Int J Pharm. 2016;515(1–2):343–351.
   PubMed Web of Science ®Google Scholar
• Baelo A, Levato R, Julián E, Crespo A, Astola J, Gavaldà J. Disassembling bacterial extracellular matrix with DNase-coated nanoparticles to enhance antibiotic delivery in biofilm infections. J Control Release. 2015;209:150–158. doi:10.1016/j.jconrel.2015.04.028
   PubMed Web of Science ®Google Scholar
• Thomas N, Thorn C, Richter K, Thierry B, Prestidge C. Efficacy of poly-lactic-co-glycolic acid micro- and nanoparticles of ciprofloxacin against bacterial biofilms. J Pharm Sci. 2016;105:1–8.
   Web of Science ®Google Scholar
• Hadinoto K, Cheow WS. Nano-antibiotics in chronic lung infection therapy against Pseudomonas aeruginosa. Colloids Surf B Biointerfaces. 2014;116:772–785. doi:10.1016/j.colsurfb.2014.02.032
   PubMed Web of Science ®Google Scholar
• Cipolla D, Wu H, Eastman S, Redelmeier R, Gonda I, Chan H. Development and characterization of an in vitro release assay for liposomal ciprofloxacin for inhalation. J Pharm Sci. 2014;103(1):314–327. doi:10.1002/jps.23795
   Web of Science ®Google Scholar
• Ong HX, Benaouda F, Traini D, et al. In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulization. Eur J Pharmaceut Biopharmaceut. 2014;86(1):83–89. doi:10.1016/j.ejpb.2013.06.024
   Web of Science ®Google Scholar
• Page-Clisson ME, Pinto-Alphandary H, Chachaty E, Couvreur P, Andremont A. Drug targeting by polyalkylcyanoacrylate nanoparticles is not efficient against persistent Salmonella. Pharm Res. 1998;15(4):544–549. doi:10.1023/A:1011921608964
   Web of Science ®Google Scholar
• Chono S, Tanino T, Seki T, Morimoto K. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J Control Release. 2008;127(1):50–58. doi:10.1016/j.jconrel.2007.12.011
   PubMed Web of Science ®Google Scholar
• Magallanes M, Dijkstra J, Fierer J. Liposome-incorporated ciprofloxacin in treatment of murine salmonellosis. Antimicrob Agents Chemother. 1993;37(11):2293–2297. doi:10.1128/AAC.37.11.2293
   PubMed Web of Science ®Google Scholar
• Hsu CY, Sung CT, Aljuffali IA, Chen CH, Hu KY, Fang JY. Intravenous anti-MRSA phosphatiosomes mediate enhanced affinity to pulmonary surfactants for effective treatment of infectious pneumonia. Nanomed Nanotechnol Biol Med. 2018;14(2):215–225. doi:10.1016/j.nano.2017.10.006
   PubMed Web of Science ®Google Scholar
• Ong HX, Traini D, Cipolla D, et al. Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia. Pharm Res. 2012;29:3335–3346.
   PubMed Web of Science ®Google Scholar
• Antoniu SA. Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa. Expert Rev Anti Infect Ther. 2012;10(12):1439–1446. doi:10.1586/eri.12.136
   PubMed Web of Science ®Google Scholar
• Yanagihara K. Design of anti-bacterial drug and anti-mycobacterial drug for drug delivery system. Curr Pharm Des. 2002;8(6):475–482. doi:10.2174/1381612023395808
   Web of Science ®Google Scholar
• Mehanna MM, Elmaradny HA, Samaha MW. Mucoadhesive liposomes as ocular delivery system: physical, microbiological, and in vivo assessment Mucoadhesive liposomes in ocular delivery. Drug Dev Ind Pharm. 2010;36(1):108–118. doi:10.3109/03639040903099751
   PubMed Web of Science ®Google Scholar
• Zhang J, Ma PX. Host-guest interaction mediated polymeric core-shell assemblies: versatile nanocarriers for drug delivery. Angew Chem Int Ed. 2009;48(5):964–968. doi:10.1002/anie.200804135
   Web of Science ®Google Scholar
• Chen M, Xie S, Wei J, Song X, Ding Z, Li X. Antibacterial micelles with vancomycin-mediated targeting and pH/lipase-triggered release of antibiotics. ACS Appl Mater Interfaces. 2018;10(43):36814–36823. doi:10.1021/acsami.8b16092
   PubMed Web of Science ®Google Scholar
• Taha EI, Badran MM, El-Anazi MH, Bayomi MA, El-Bagory IM. Role of pluronic F127 micelles in enhancing ocular delivery of ciprofloxacin. J Mol Liq. 2014;199(2014):251–256. doi:10.1016/j.molliq.2014.09.021
   Web of Science ®Google Scholar
• Zadeh M, Sharif B, Esfahani G, Salimi Y. Permeability of ciprofloxacin-loaded polymeric micelles including ginsenoside as P-glycoprotein inhibitor through a Caco-2 cells monolayer as an intestinal absorption model. Molecules. 2018;23(8):1904. doi:10.3390/molecules23081904
   Web of Science ®Google Scholar
• Garhwal R, Shady SF, Ellis EJ, et al. Sustained ocular delivery of ciprofloxacin using nanospheres and conventional contact lens materials. IOVS. 2012;53(3):1341–1352.
   PubMed Web of Science ®Google Scholar
• Fawaz F, Bonini F, Maugein J, Lagueny AM. Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: pharmacokinetics and in vitro antimicrobial activity. Int J Pharm. 1998;168(2):255–259. doi:10.1016/S0378-5173(98)00116-1
   Web of Science ®Google Scholar
• Kumar GS, Govindan R, Girija EK. In situ synthesis, characterization and in vitro studies of ciprofloxacin loaded hydroxyapatite nanoparticles for the treatment of osteomyelitis. J Mater Chem B. 2014;2(31):5052–5060. doi:10.1039/c4tb00339j
   PubMed Web of Science ®Google Scholar
• Panda BP, Patnaik S, Maharana RL. Current trends in design and development of nanopharmaceutical dosage forms. Bioequiv Bioavailab Int J. 2017;1(1):000104.
   Google Scholar
• Kooti M, Sedeh AN, Motamedi H, Rezatofighi SE. Magnetic graphene oxide inlaid with silver nanoparticles as antibacterial and drug delivery composite. Appl Microbiol Biotechnol. 2018;102(8):3607–3621. doi:10.1007/s00253-018-8880-1
   PubMed Web of Science ®Google Scholar
• Zavarshani M, Ahmadi M, Saei HD, Tehrani AA, Naghadeh BD. Comparison therapeutic effects of ciprofloxacin, silver nanoparticles and their combination in the treatment of Pseudomonas keratitis in rabbit: an experimental study. Iran J Pharmaceut Res. 2019;18(1):320–327.
   Web of Science ®Google Scholar
• Mohsen E, El-Borady OM, Mohamed MB, Fahim IS. Synthesis and characterization of ciprofloxacin loaded silver nanoparticles and investigation of their antibacterial effect. J Radiat Res Appl Sci. 2020;13(1):416–425.
   Web of Science ®Google Scholar
• Sreedharan SM, Singh R. Ciprofloxacin functionalized biogenic gold nanoflowers as nanoantibiotics against pathogenic bacterial strains. Int J Nanomedicine. 2019;14:9905–9916.
   PubMed Web of Science ®Google Scholar
• Tom RT, Suryanarayanan V, Reddy PG, Baskaran S, Pradeep T. Ciprofloxacin-protected gold nanoparticles. Langmuir. 2004;20:1909–1914.
   PubMed Web of Science ®Google Scholar
• Nisar M, Khan SA, Qayum M, et al. Robust synthesis of ciprofloxacin-capped metallic nanoparticles and their urease inhibitory assay. Molecules. 2016;21:411.
   PubMed Web of Science ®Google Scholar
• Banoee M, Seif S, Nazari ZE, et al. ZnO nanoparticles enhanced antibacterial activity of ciprofloxacin against Staphylococcus aureus and Escherichia coli. J Biomed Mater Res B Appl Biomater. 2010;93:557.
   PubMed Web of Science ®Google Scholar
• Seif S, Kazempour ZB, Pourmand MR, et al. Preparation of ciprofloxacin-coated zinc oxide nanoparticles and their antibacterial effects against clinical isolates of Staphylococcus aureus and Escherichia coli. Arzneimittelforschung. 2011;61(8):472–476.
   Web of Science ®Google Scholar
• Allahverdiyev AM, Kon KV, Abamor ES, Bagirova M, Rafailovich M. Coping with antibiotic resistance: combining nanoparticles with antibiotics and other antimicrobial agents. Expert Rev Anti Infect Ther. 2012;9(11):1035–1052.
   Web of Science ®Google Scholar
• Auger S, Henry C, Péchoux C, et al. Exploring multiple effects of Zn0.15Mg0.85O nanoparticles on Bacillus subtilis and macrophages. Sci Rep. 2018;8:12276.
   Web of Science ®Google Scholar
• Rodrigues GR, López-Abarrategui C, de la Serna Gómez I, Dias SC, Otero-González AJ, Franco OL. Antimicrobial magnetic nanoparticles based-therapies for controlling infectious diseases. Int J Pharm. 2018;555:356–367.
   Web of Science ®Google Scholar
• El-Salamouni NS, Farid RM, El-Kamel AH, El-Gamal SS. Effect of sterilization on the physical stability of brimonidine-loaded solid lipid nanoparticles and nanostructured lipid carriers. Int J Pharm. 2015;496(2):976–983.
   PubMed Web of Science ®Google Scholar
• Zaki NM, Hafez MM. Enhanced antibacterial effect of ceftriaxone sodium-loaded chitosan nanoparticles against intracellular Salmonella typhimurium. AAPS PharmSciTech. 2012;13(2):411–421.
   PubMed Web of Science ®Google Scholar
• Mehnert W. Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2–3):165–196.
   PubMed Web of Science ®Google Scholar
• Qu J, Zhang L, Chen Z, et al. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy? Drug Deliver. 2016;23(9):3408–3416.
   PubMed Web of Science ®Google Scholar
• Pignatello R, Leonardi A, Fuochi V, Petronio G, Greco AS, Furneri PM. A method for efficient loading of ciprofloxacin hydrochloride in cationic solid lipid nanoparticles: formulation and microbiological evaluation. Nanomater. 2018;8:304.
   Web of Science ®Google Scholar
• Jain D, Banerjee R. Comparison of ciprofloxacin HCl-loaded protein, lipid, and chitosan nanoparticles for drug delivery. J Biomed Mater Res B Appl Biomater. 2008;86B(1):105–112.
   Web of Science ®Google Scholar
• Shazly GA. Ciprofloxacin controlled-solid lipid nanoparticles: characterization, in vitro release, and antibacterial activity assessment. Biomed Res Int. 2017;2017:2120734.
   Web of Science ®Google Scholar